清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data

医学 内科学 乳腺癌 肿瘤科 雌激素受体 比例危险模型 阶段(地层学) 癌症 疾病 化疗 妇科 古生物学 生物
作者
Dimitrios Zardavas,Luc te Marvelde,Roger L. Milne,Debora Fumagalli,George Fountzilas,Vassiliki Kotoula,Evangelia Razis,George Papaxoinis,Heikki Joensuu,Mary Ellen Moynahan,Bryan T. Hennessy,Ivan Bièche,Lao H. Saal,Olle Stål,Barry Iacopetta,Jeanette Dupont Jensen,Sandra A. O’Toole,Elena López‐Knowles,Mattia Barbaraeschi,Shinzaburo Noguchi
出处
期刊:Journal of Clinical Oncology [American Society of Clinical Oncology]
卷期号:36 (10): 981-990 被引量:121
标识
DOI:10.1200/jco.2017.74.8301
摘要

Purpose Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit alpha ( PIK3CA) mutations are frequently observed in primary breast cancer. We evaluated their prognostic relevance by performing a pooled analysis of individual patient data. Patients and Methods Associations between PIK3CA status and clinicopathologic characteristics were tested by applying Cox regression models adjusted for age, tumor size, nodes, grade, estrogen receptor (ER) status, human epidermal growth factor receptor 2 (HER2) status, treatment, and study. Invasive disease-free survival (IDFS) was the primary end point; distant disease-free survival (DDFS) and overall survival (OS) were also assessed, overall and by breast cancer subtypes. Results Data from 10,319 patients from 19 studies were included (median OS follow-up, 6.9 years); 1,787 patients (17%) received chemotherapy, 4,036 (39%) received endocrine monotherapy, 3,583 (35%) received both, and 913 (9%) received none or their treatment was unknown. PIK3CA mutations occurred in 32% of patients, with significant associations with ER positivity, increasing age, lower grade, and smaller size (all P < .001). Prevalence of PIK3CA mutations was 18%, 22%, and 37% in the ER-negative/HER2-negative, HER2-positive, and ER-positive/HER2-negative subtypes, respectively. In univariable analysis, PIK3CA mutations were associated with better IDFS (HR, 0.77; 95% CI, 0.71 to 0.84; P < .001), with evidence for a stronger effect in the first years of follow-up (0 to 5 years: HR, 0.73; 95% CI, 0.66 to 0.81; P < .001; 5 to 10 years: HR, 0.82; 95% CI, 0.68 to 0.99; P = .037); > 10 years: (HR, 1.15; 95% CI, 0.84 to 1.58; P = .38; P heterogeneity = .02). In multivariable analysis, PIK3CA genotype remained significant for improved IDFS ( P = .043), but not for the DDFS and OS end points. Conclusion In this large pooled analysis, PIK3CA mutations were significantly associated with a better IDFS, DDFS, and OS, but had a lesser prognostic effect after adjustment for other prognostic factors.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
8秒前
vibe发布了新的文献求助10
13秒前
加贝火火完成签到 ,获得积分10
19秒前
周娅敏完成签到,获得积分20
24秒前
HYQ完成签到 ,获得积分10
1分钟前
搜集达人应助顺利代曼采纳,获得10
1分钟前
1分钟前
1分钟前
陶醉的烤鸡完成签到 ,获得积分10
1分钟前
sonicker完成签到 ,获得积分10
1分钟前
顺利代曼发布了新的文献求助10
1分钟前
愉快的犀牛完成签到 ,获得积分10
2分钟前
2分钟前
飞龙在天完成签到 ,获得积分10
2分钟前
3分钟前
3分钟前
卢雨生发布了新的文献求助10
3分钟前
3分钟前
Marco_hxkq发布了新的文献求助10
3分钟前
冷傲半邪完成签到,获得积分10
4分钟前
两个榴莲完成签到,获得积分0
4分钟前
Ava应助Antares采纳,获得20
5分钟前
amen完成签到 ,获得积分10
5分钟前
5分钟前
6分钟前
大个应助研究XPD的小麻薯采纳,获得10
7分钟前
小丸子完成签到 ,获得积分0
7分钟前
7分钟前
Antares发布了新的文献求助20
7分钟前
7分钟前
7分钟前
研究XPD的小麻薯完成签到,获得积分10
7分钟前
7分钟前
firefox完成签到,获得积分10
8分钟前
8分钟前
firefox发布了新的文献求助10
8分钟前
赘婿应助yang采纳,获得10
8分钟前
赘婿应助顺利代曼采纳,获得10
8分钟前
8分钟前
ikouyo完成签到 ,获得积分10
8分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 生物化学 化学工程 物理 计算机科学 复合材料 内科学 催化作用 物理化学 光电子学 电极 冶金 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6021356
求助须知:如何正确求助?哪些是违规求助? 7630170
关于积分的说明 16166423
捐赠科研通 5169154
什么是DOI,文献DOI怎么找? 2766269
邀请新用户注册赠送积分活动 1749034
关于科研通互助平台的介绍 1636369